Bone marrow disorder
MONDO:0003225Any disease of the bone marrow.
Also known as: bone marrow disease, bone marrow disease or disorder, bone marrow disorder, disease of bone marrow, disease or disorder of bone marrow, disorder of bone marrow
1761 clinical trials for this condition and its sub-types, 18 tagged with Bone marrow disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Bone marrow disorder
-
Bone marrow neoplasm 3 trials · 1,631 incl. sub-types
1 sub-type
- Bone marrow cancer 2 trials · 1,631 incl. sub-types Sub-types →
-
Polycythemia 9 trials · 99 incl. sub-types
5 sub-types
- Familial polycythemia 1 trial · 92 incl. sub-types Sub-types →
- Secondary polycythemia 2 trials Sub-types →
- Acquired polycythemia 0 trials Sub-types →
- Physiological polycythemia 0 trials
- Polycythemia neonatorum 0 trials
-
Bone marrow failure syndrome 48 trials
8 sub-types
- AMED syndrome, digenic 0 trials
- Ziegler-Huang syndrome 0 trials
- Autosomal dominant aplasia and myelodysplasia 0 trials
- Bone marrow failure syndrome 3 0 trials
- Bone marrow failure syndrome 4 0 trials
- Bone marrow failure syndrome 5 0 trials
- Bone marrow failure syndrome 6 0 trials
- Pancytopenia-developmental delay syndrome 0 trials
-
Osteomyelitis 43 trials · 46 incl. sub-types
2 sub-types
- Chronic recurrent multifocal osteomyelitis 3 trials · 4 incl. sub-types Sub-types →
- Petrositis 0 trials
-
Fanconi anemia 29 trials · 42 incl. sub-types
22 sub-types
- Fanconi anemia complementation group D1 6 trials
- Fanconi anemia complementation group A 4 trials
- Fanconi anemia complementation group E 4 trials
- Fanconi anemia complementation group N 2 trials
- Fanconi anemia, complementation group S 2 trials
- Fanconi anemia complementation group B 0 trials
- Fanconi anemia complementation group C 0 trials
- Fanconi anemia complementation group D2 0 trials
- Fanconi anemia complementation group F 0 trials
- Fanconi anemia complementation group G 0 trials
- Fanconi anemia complementation group I 0 trials
- Fanconi anemia complementation group J 0 trials
- Fanconi anemia complementation group L 0 trials
- Fanconi anemia complementation group O 0 trials
- Fanconi anemia complementation group P 0 trials
- Fanconi anemia complementation group Q 0 trials
- Fanconi anemia complementation group R 0 trials
- Fanconi anemia complementation group T 0 trials
- Fanconi anemia complementation group U 0 trials
- Fanconi anemia complementation group V 0 trials
- Fanconi anemia, complementation group W 0 trials
- Fanconi anemia, complementation group 10 0 trials
-
Drachtman Weinblatt Sitarz syndrome 0 trials
-
Premature ovarian failure 15 0 trials
Most studied deeper sub-types
-
New hope for rare blood cancers: pacritinib trial opens for teens and adults
Disease control Recruiting nowThis study tests an oral drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers (MDS/MPN). The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cell therapy aims to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis phase 2 trial is testing a new treatment called Orca-T for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Orca-T is a personalized cell therapy made from a donor's blood that includes stem cells and immune cells. The goal is to see if it can impr…
Phase 2 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill aims to shrink spleen and ease symptoms in hard-to-treat bone marrow cancer
Disease control Recruiting nowThis early-phase study tests an oral drug called PMD-026 in 18 adults with myelofibrosis, a type of bone marrow cancer. Participants must have already tried a JAK inhibitor without success. The main goals are to check safety, find the best dose, and see if the drug can shrink the…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Scientists study mast cells to unlock mastocytosis mysteries
Knowledge-focused Recruiting nowThis study collects bone marrow and blood samples from up to 600 people with mastocytosis, a condition where too many mast cells cause symptoms like itching and bone pain. Researchers will study what makes these cells grow and survive. The goal is to learn more about the disease,…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can discarded bone reveal the secrets to stronger bones?
Knowledge-focused Recruiting nowThis study aims to understand why bones weaken with age, leading to conditions like osteoporosis and osteoarthritis. Researchers will collect bone waste and blood samples from 2,000 people undergoing orthopedic surgery, including those with and without bone disease. By analyzing …
Sponsor: Relation Therapeutics • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
New study measures radioactive drug safety in vulnerable patients
Knowledge-focused Recruiting nowThis study looks at how much of the radioactive drug Pluvicto reaches tumors and organs in patients whose kidneys or bone marrow are not working well. About 25 people will be enrolled to check for side effects and safety. The goal is to better understand dosing in these patients,…
Phase 4 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC